CEL-SCI

CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CEL-SCI Corp. is a biotechnology company, which engages in the research, development and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI to Conduct Investor Call Regarding Phase 3 Results Following Annual Shareholder Meeting on July 1, 2021

CEL-SCI to Conduct Investor Call Regarding Phase 3 Results Following Annual Shareholder Meeting on July 1, 2021

Everything went the wrong way for Cel-Sci.

Will All End Well for This Popular Reddit Biotech?

Today, the trial results reported by Cel-Sci missed the mark, and investors are pricing in additional risks with CVM stock. The post CVM Stock: The Big Trial News That Has Cel-Sci Plunging Today appeared first on InvestorPlace.

CVM Stock: The Big Trial News That Has Cel-Sci Plunging Today

CEL-SCI Corporation (NYSE: CVM) has announced results from its Phase 3 study for its immunotherapy Multikine for advanced previously untreated squamous cell carcinoma of the head and neck (SCCHN). In the intent to treat patients, the study showed a statistically significant overall survival benefit of 14.1% with overall survival of 62.7% at five years for the group of patients receiving the Multikine treatment regimen followed by surgery and radiotherapy therapy, but not chemotherapy, as part of their standard of care treatment.

CEL-SCI's Immunotherapy Achieves Survival Benefit Of 14% Exceeding Pre-Defined 10% In Head & Cancer Patients

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--Multikine immunotherapy produces significant 14.1% 5-Year survival benefit in group receiving surgery plus radiotherapy in landmark Phase 3 Study.

CEL-SCI's Multikine® Immunotherapy Produces Significant 14.1% 5-Year Survival Benefit (62.7% Vs 48.6%) in the Group Receiving Surgery Plus Radiotherapy in a Landmark Head and Neck Cancer Phase 3 Study

VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI Corporation invites participants to pre-submit questions for Annual Shareholder Meeting.

CEL-SCI Corporation Invites Participants to Pre-Submit Questions for Annual Shareholder Meeting

VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces the closing of $31.7 million bought deal offering.

CEL-SCI Announces the Closing of $31.7 Million Bought Deal Offering

CEL-SCI Corporation (NYSE: CVM) has increased the size of its previously announced capital raise offering to 1.4 million shares, up from 1 million shares, at $22.62 per share representing a 5% discount to Tuesday's closing price of $23.82 per share. The offering is expected to close by June 11.

CEL-SCI Stock Drops After Raising $37.1M Via Secondary Equity Offering

VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI Increases Previously Announced Bought Deal to $31.7 Million.

CEL-SCI Increases Previously Announced Bought Deal to $31.7 Million

VIENNA, Va.--(BUSINESS WIRE)-- #CVM--CEL-SCI Announces Bought Deal Offering

CEL-SCI Announces Bought Deal Offering

Big news is coming for CEL-SCI, and we don't know which way the stock will move.

Can You Count on This Popular Reddit Cancer-Treatment Stock?

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation reports second quarter fiscal 2021 financial results.

CEL-SCI Corporation Reports Second Quarter Fiscal 2021 Financial Results

The stock price of CEL-SCI Corporation (NYSEAMERICAN: CVM) increased by over 5% during intraday trading. This is why it happened.

CVM Stock: Over 5% Increase Intraday Explanation

Full data analysis readout is expected in a few weeks. Multikine will change the Standard of Care if successful.

Cel-Sci: Multikine To Change Standard Of Care

Castor Maritime Inc

Marathon Oil

Spectrum Pharma

cbdMD Inc

Reddit stocks always make noise across social media platforms. But these investments have serious catalysts connected to them.

7 Reddit Stocks With Upcoming Catalysts To Watch

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation reports first quarter fiscal 2021 financial results.

CEL-SCI Corporation Reports First Quarter Fiscal 2021 Financial Results

AMC Entertainment

BlackBerry

Investors are betting that these three stocks could turn them into millionaires in incredibly short periods of time. Will they succeed?

Should You Buy These 3 Hot Reddit Stocks Before It's Too Late?

CVM stock is on the move after Cel-Sci CEO Geert Kersten joined the battle against GME stock short-sellers. Here's what to know.

CVM Stock: Why Cancer Play Cel-Sci Is Riding the Reddit Wave

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation to Present at the 2021 H.C. Wainwright BIOCONNECT Virtual Conference

CEL-SCI Corporation to Present at the 2021 H.C. Wainwright BIOCONNECT Virtual Conference

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI reports fiscal 2020 financial results and clinical & corporate developments.

CEL-SCI Reports Fiscal 2020 Financial Results and Clinical & Corporate Developments

Data lock has been announced, and top line data is to be expected within a few weeks. Trial duration hints towards longer survival than Standard of Care.

Cel-Sci Long Awaited Head And Neck Trial Phase III: Data Locked

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation to Present at the 13th Annual LD Micro Main Event Conference

CEL-SCI Corporation to Present at the 13th Annual LD Micro Main Event Conference

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI announces the closing of its $14.65 million bought deal.

CEL-SCI Announces the Closing of Its $14.65 Million Bought Deal

Data is Locked. NWBO's Data Lock announcement boosted their Market Cap to nearly $2B.

CEL-SCI: Data Locked

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Announces Update on Phase 3 Cancer Trial Results.

News for CEL-SCI Stock (CVM)